Synergistic antitumor effect of puerarin combined with 5-fluorouracil on gastric carcinoma

Guo,Xu‑Feng; Yang,Zi‑Rong; Wang,Jun; Lei,Xiao‑Fei; Lv,Xiao‑Guang; Dong,Wei‑Guo

doi:10.3892/mmr.2014.3016

Synergistic antitumor effect of puerarin combined with 5-fluorouracil on gastric carcinoma

Authors:
- Xu‑Feng Guo
- Zi‑Rong Yang
- Jun Wang
- Xiao‑Fei Lei
- Xiao‑Guang Lv
- Wei‑Guo Dong
View Affiliations

Affiliations: Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: November 27, 2014 https://doi.org/10.3892/mmr.2014.3016
Pages: 2562-2568
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Combination chemotherapy is a crucial method in the treatment of gastric cancer. The aim of the present study was to investigate the inhibitory effects of puerarin and 5‑fluorouracil (5‑FU) on BGC‑823 gastric cancer cells in vitro and in vivo. The in vitro growth inhibition of puerarin or 5‑FU alone or combined on BGC‑823 cells was determined using a cell counting kit 8 (CCK‑8) on living cells. Apoptotic morphological features and proteins expression levels were detected by Hoechst 33258 staining, an Annexin V/propidium iodide apoptosis kit and western blot analysis, respectively. Tumor xenografts were established in nude mice and the inhibitory effects and side effects were detected. Results of the CCK‑8, Hoechst 33258 staining and flow cytometry revealed that the combined treatment was more effective than the separate treatments. The tumor volume was 90.65% of that of the controls and the mean tumor weight was only 0.125 g at the end of the experiment in the combination group compared with the control group (0.822 g). In addition, it was determined that liver and renal toxicity did not increase in combined treatment. These findings showed that puerarin and 5‑FU produced a significant synergic effect on gastric cancer cells, while there was no increase in side effects.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008. GLOBOCAN. 2008. Int J Cancer. 127:2893–2917. 2008. View Article : Google Scholar
3	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geo-graphic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
4	Ahn MS, Kang SY, Lee HW, Jeong SH, Park JS, Lee KJ, et al: 5-fluorouracil, mitomycin-C, and polysaccharide-K versus uracil-ftorafur and polysaccharide-K as adjuvant chemoimmunotherapy for patients with locally advanced gastric cancer with curative resection. Onkologie. 36:421–426. 2013. View Article : Google Scholar : PubMed/NCBI
5	Yanagihara K, Ito A, Toge T and Numoto M: Antiproliferative efects ofisoflavones on human cancer cell lines established from the gastrointestinal tract. Cancer Res. 53:5815–5821. 1993.PubMed/NCBI
6	Tian F, Xu LH, Zhao W, Tian LJ and Ji XL: The optimal therapeutic timing and mechanism of puerarin treatment of spinal cord ischemia-reperfusion injury in rats. J Ethnopharmacol. 134:892–896. 2011. View Article : Google Scholar : PubMed/NCBI
7	Yuan Y, Zong J, Zhou H, Bian ZY, Deng W, Dai J, et al: Puerarin attenuates pressure overload-induced cardiac hypertrophy. J Cardiol. 63:73–81. 2014. View Article : Google Scholar
8	Zhao LX, Liu AC, Yu SW, Wang ZX, Lin XQ, Zhai GX and Zhang QZ: The permeability of puerarin loaded poly (butylcyanoacrylate) nanoparticles coated with polysorbate 80 on the blood-brain barrier and its protective effect against cerebral ischemia/reperfusion injury. Biol Pharm Bull. 36:1263–1270. 2013. View Article : Google Scholar
9	Kim KM, Jung DH, Jang DS, Kim YS, Kim JM, Kim HN, Surh YJ and Kim JS: Puerarin suppresses AGEs-induced inflammation in mouse mesangial cells: a possible pathway through the induction of heme oxygenase-1 expression. Toxicol Appl Pharmacol. 244:106–113. 2010. View Article : Google Scholar : PubMed/NCBI
10	Yu Z and Li W: Induction of apoptosis by puerarin in colon cancer HT-29 cells. Cancer Lett. 238:53–60. 2006. View Article : Google Scholar
11	Wang Y, Ma Y, Zheng Y, Song J, Yang X, Bi C, Zhang D and Zhang Q: In vitro and in vivo anticancer activity of a novel puerarin nanosuspension against colon cancer, with high efficacy and low toxicity. Int J Pharm. 441:728–735. 2013. View Article : Google Scholar
12	Chou TC and Talalay P: Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar
13	Chou TC, Motzer RJ, Tong Y and Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst. 86:1517–1524. 1994. View Article : Google Scholar : PubMed/NCBI
14	Ashraf N, Hoffe S and Kim R: Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist. 18:1013–1021. 2013. View Article : Google Scholar : PubMed/NCBI
15	Imazawa M, Kojima T, Boku N, Onozawa Y, Hironaka S, et al: Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination. Gastric Cancer. 12:153–157. 2009. View Article : Google Scholar : PubMed/NCBI
16	Kim SL, Kim SH, Trang KT, Kim IH, Lee SO, et al: Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer. Cancer Lett. 335:479–486. 2013. View Article : Google Scholar : PubMed/NCBI
17	Wang J, Liu W, Zhao Q, Qi Q, Lu N, et al: Synergistic effect of 5-fluorouracil with gambogic acid on BGC-823 human gastric carcinoma. Toxicology. 256:135–140. 2009. View Article : Google Scholar
18	Nishino T, Yamamoto Y, Ikeda M, Morimoto M, Furukawa T, Goto M, Furukita Y, Takechi H, Seike J, Tangoku A and Fujiwara H: Pathological complete response in a case of advanced esopha-geal cancer invading aorta treated by preoperative chemotherapy with docetaxel and cisplatin plus 5-FU. Gan To Kagaku Ryoho. 40:643–646. 2013.(In Japanese). PubMed/NCBI
19	Wang L, Wei PK and Xu YP: Experimental study on puerarin injection reverse multidrug resistance of nude mice of human gastric carcinoma constructed using orthotopic transplantation. J Chendu Uni TCM. 28:42–46. 2005.(In Chinese).
20	Hien TT, Kim HG, Han EH, Kang KW and Jeong HG: Molecular mechanism of suppression of MDR1 by puerarin from pueraria lobata via NF-kappaB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells. Mol Nutr Food Res. 54:918–928. 2010. View Article : Google Scholar : PubMed/NCBI
21	Han P, Pei LY, Li J, Zhang L, Zhang HQ and Xu D: Effect and mechanism of pueraria crude extract puerarin on lung cancer H446 cell proliferation. Shandong Med J. 48:7–9. 2008.